WDC Journal

Treating AVMs with rapamycine and bleomycine: about 3 cases

Aicha Salhi — 2025-10-15

Arteriovenous malformations (AVMs) are complex vascular
anomalies characterized by direct connections between dysplastic
arteries and dilated veins. They often present during
puberty or adulthood, most frequently in the head and
neck, and may cause complications such as pain, ulceration,
bleeding, or high-output cardiac failure. Conventional
management with embolization and surgery can be hazardous,
while novel biologics are not always accessible. We report
three cases of AVMs treated with a combined regimen
of systemic rapamycin and perilesional bleomycin injections.
The first patient, a 12-year-old girl with a breast AVM, achieved
sustained stability after two years of treatment and seven years
of follow-up. The second, a 31-year-old woman with a labial AVM,
showed complete and durable regression after three years of therapy
and six years of follow-up. The third, a 29-year-old woman
with a cheek AVM, experienced significant clinical and hemodynamic
improvement following two years of combined treatment,
after pregnancies had initially limited therapeutic options.
These cases highlight the efficacy and tolerability of rapamycin
plus bleomycin in controlling AVMs, avoiding disfiguring or
high-risk surgery. The findings suggest that this combination
may represent a valuable therapeutic option in settings
where embolization or advanced biologics are unavailable.

Therapeutic education in atopic dermatitis: Results from an observationnal cohort

Samira Zobiri — 2025-09-24

Atopic dermatitis (AD) is a chronic inflammatory disease that requires therapeutic patient education (TPE). In the derma-tology department, we initiated a therapeutic education pro-gram for patients with AD. This study aims to describe our therapeutic education activity. We conducted a single-center, prospective, observational study at the Dermatology Depart-ment of Mustapha Hospital in Algiers, including all patients with moderate-to-severe AD (SCORAD ≥ 25) observed between January 2024 and June 2024. Demographic data, SCORAD, and the Numerical Rating Scale (NRS) for pruritus were col-lected. Thirty-five patients with AD were enrolled, and all par-ticipants attended three therapeutic education sessions. The mean NRS pruritus score was 7 at baseline and decreased to 4 after six months. The mean SCORAD was 34.6 at baseline and 21.2 at six months. TPE is an integral part of the mana-gement of AD and is recommended in international guidelines. Numerous studies have demonstrated its effectiveness in re-ducing pruritus, disease severity, and improving quality of life. Our results highlight the value of atopy schools in the mana-gement of AD. The development of educational structures is essential for the treatment of chronic dermatological diseases.

Molecular Identification of the species that cause leprosy

J. L. Mayorga Garibaldi — 2025-11-07

Leprosy or Hansen’s disease is a chronic granulomatous di-sease that mainly affects the skin and peripheral nerves, cau-sed by Mycobacterium leprae, from the point of view of the bacteriological index by means of bacilloscopies or histopa-thology, with Ziehl Neelsen or Kinyoun staining, it is classi-fied in multibacillary patients, those patients whose bacillo-scopy contains more than 2 bacilli in 100 fields observed under the microscope in 100X objective. (BB, BL and LL) or pauci-bacillary (PB) with less than 2 bacilli, (BB, BT and TT).